Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of paclitaxel polymeric micelles plus gemcitabine versus nab-paclitaxel plus gemcitabine as first-line treatment for metastatic pancreatic cancer
CTR20244818Phase 3Active
- Sponsor
- Shanghai Yizhong Pharmaceutical Co., Ltd.
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of paclitaxel, gemcitabine in pancreatic cancer (PC), sponsored by Shanghai Yizhong Pharmaceutical Co., Ltd.. Started Feb 2025; status: active.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20244818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244818.